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Abstract
Introduction: To investigate the effects of G-CSF or GM-CSF therapy in non-neutropenic patients with sepsis.
Methods: A systematic literature search of Medline, Embase and Cochrane Central Register of Controlled Trials was
conducted using specific search terms. A manual review of references was also performed. Eligible studies were
randomized control trials (RCTs) that compared granulocyte-colony stimulating factor (G-CSF) or granulocyte-
macrophage colony stimulating factor (GM-CSF) therapy with placebo for the treatment of sepsis in adults. Main
outcome measures were all-cause mortality at 14 days and 28 days after initiation of G-CSF or GM-CSF therapy, in-
hospital mortality, reversal rate from infection, and adverse events.
Results: Twelve RCTs with 2,380 patients were identified. In regard to 14-day mortality, a total of 9 death events
occurred among 71 patients (12.7%) in the treatment group compared with 13 events among 67 patients (19.4%)
in the placebo groups. Meta-analysis showed there was no significant difference in 28-day mortality when G-CSF or
GM-CSF were compared with placebo (relative risks (RR) = 0.93, 95% confidence interval (CI): 0.79 to 1.11, P = 0.44;
P for heterogeneity = 0.31, I
2 = 15%). Compared with placebo, G-CSF or GM-CSF therapy did not significantly
reduce in-hospital mortality (RR = 0.97, 95% CI: 0.69 to 1.36, P = 0.86; P for heterogeneity = 0.80, I
2 = 0%). However,
G-CSF or GM-CSF therapy significantly increased the reversal rate from infection (RR = 1.34, 95% CI: 1.11 to 1.62,
P = 0.002; P for heterogeneity = 0.47, I
2 = 0%). No significant difference was observed in adverse events between
groups (RR = 0.93, 95% CI: 0.70 to 1.23, P = 0.62; P for heterogeneity = 0.03, I
2 = 58%). Sensitivity analysis by
excluding one trial did not significantly change the results of adverse events (RR = 1.05, 95% CI: 0.84 to 1.32,
P = 0.44; P for heterogeneity = 0.17, I
2 = 36%).
Conclusions: There is no current evidence supporting the routine use of G-CSF or GM-CSF in patients with sepsis.
Large prospective multicenter clinical trials investigating monocytic HLA-DR (mHLA-DR)-guided G-CSF or GM-CSF
therapy in patients with sepsis-associated immunosuppression are warranted.
Introduction
Despite improvements in antimicrobial therapy and sup-
portive care, the incidence of sepsis continues to rise
and sepsis is now the third leading cause of infectious
deaths in the United States [1], with a mortality rate
ranging from 20% for sepsis to 50% for septic shock
[2,3]. During the past decades, many clinical trials test-
ing anti-inflammatory therapies have been performed.
However, the effects of these approaches on patient
mortality were rather disappointing [4-7]. It is now gen-
erally agreed that patients with sepsis are more prone to
die in a state of sepsis-induced immunosuppression,
including reduced monocytic phagocytotic activity,
changes in monocytic cytokine expression, diminished
monocytic antigen presentation, lymphocytic dysfunc-
tion and apoptosis-induced loss of circulating T-and
B-lymphocytes [4,8-21]. Consequently, immunostimula-
tory therapies constitute an innovative strategy that
deserves to be assessed for the treatment of sepsis
[14,22,23].
To date, one approach is the use of granulocyte colony
stimulating factor (G-CSF) or granulocyte-macrophage
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cell functions in patients with sepsis. G-CSF, widely used
in reducing the duration of febrile neutropenia following
cytotoxic chemotherapy, has been shown to stimulate the
production of neutrophils and modulate the function and
activity of developing and mature neutrophils [24]. Com-
p a r e dt oG - C S F ,G M - C S Fe x h i b i t sb r o a d e re f f e c t sa n d
induces proliferation and differentiation of neutrophils,
monocytes, macrophages, and myeloid-derived dendritic
cells. GM-CSF has been demonstrated to increase mono-
cytic HLA-DR (mHLA-DR) expression and endotoxin-
induced proinflammatory cytokine production in ex vivo
whole blood cultures of patients with severe sepsis
[25,26].
So far, G-CSF and GM-CSF have shown promise in
the treatment of infection in non-neutropenic hosts in
many animal models [27-30]. Additionally, several clini-
cal trials have been conducted to investigate the effect
of G-CSF or GM-CSF treatment in neonates and adults
with infection. Recently, a meta-analysis investigating
the effect of G-CSF and GM-CSF for treating neonatal
infection showed no significant reduction in 14-day
mortality [31]. To our best knowledge, no previous sys-
tematic review had been conducted to define the effi-
cacy and safety of G-CSF and GM-CSF in patients with
sepsis. Therefore, we attempted to summarize the avail-
able randomized control trials (RCTs) to determine
whether G-CSF or GM-CSF therapy significantly
reduced all-cause mortality at 14 days and 28 days, in-
hospital mortality and occurrence of adverse events, and
increased reversal rate from infection in patients with
sepsis.
Materials and methods
We followed the guidelines of Preferred Reporting Items
for Systematic Reviews and Meta-Analyses for reporting
our meta-analysis and results [32].
Search strategy
We searched Pubmed, Embase, and the Cochrane Cen-
tral Register of Controlled Trials (to 25 October 2010)
to identify potentially relevant trials. We restricted the
search to trials on adults and used the search terms
“granulocyte colony-stimulating factor”, “granulocyte
colony stimulating factor, recombinant”, “GCSF”, “fil-
grastim”, “lenograstim”, “sargramostim”, “pegfilgrastim”,
“granulocyte-macrophage colony-stimulating factor”,
“granulocyte-macrophage colony stimulating factor,
recombinant”, “GMCSF”, “molgramostim”,A N D“sep-
sis”, “septicemia”, “septicaemia”, “septic shock”.W e
restricted the findings of this search with a highly sensi-
tive search strategy recommended by the Cochrane Col-
laboration for identifying all randomized controlled
trials [33]. In addition, we checked the reference lists of
identified trials and previous relevant meta-analyses
identified by the electronic search to find other poten-
tially eligible trials. There was no language restriction
for the search. Authors of papers were contacted when
results were unclear or when relevant data were not
reported.
Study selection
We considered trials that investigated the therapeutic
effects of G-CSF or GM-CSF administered intravenously
or subcutaneously in adults with sepsis. Sepsis was
defined according to the American College of Chest
Physicians/Society of Critical Care Medicine consensus
criteria [34] or was extrapolated to these criteria if not
provided. Trials that allowed concurrent use of other
therapies, including antibiotics, mechanical ventilation,
steroids, bronchodilators and so on were included if
they allowed equal access to such medications for
patients in both arms of the trial. Randomized con-
trolled trials specifically involving neutropenic patients
or patients following chemotherapy were excluded.
Agreement between reviewers regarding trial inclusion
was assessed using the Cohen К statistic [35].
Data extraction
Full text versions of all eligible trials were obtained for
quality assessment and data extraction independently by
two reviewers. Extracted data were entered into Micro-
soft Excel 2007 and were checked by a third reviewer.
Disagreement or doubt was resolved by discussion.
Abstracted data included study design (for example,
date of conduct and sample size), patient characteristics,
study methodology (for example, eligibility criteria,
method of randomization, and blinding), intervention
(for example, G-CSF and GM-CSF dosage, duration and
route of administration) and main outcomes. The qual-
ity of trials was assessed with the methods recom-
mended by the Cochrane Collaboration for assessing
risk of bias [36]. The criteria used for quality assessment
were sequence generation of allocation, allocation con-
cealment, blinding, selective outcome reporting and
other sources of bias. Each criterion was categorized as
‘yes’, ‘no’,o r‘unclear’, and the summary assessments of
the risk of bias for each important outcome within and
across studies was categorized as ‘low risk of bias’,
‘unclear risk of bias’ and ‘high risk of bias’.
The primary outcomes of this meta-analysis were all-
cause mortality at 14 days and 28 days after initiation of
G-CSF or GM-CSF therapy. Secondary outcomes
included in-hospital mortality, reversal rate from infec-
tion, and adverse events. The definition of reversal of
infection referred to resolution of all signs, symptoms
and laboratory assessment of infection or recovery from
sepsis, which varied among trials due to different origins
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tion that was life threatening, required treatment and
prolongation hospitalization, or was associated with
death of the patient.
Statistical analysis
Analyses were on an intention-to-treat basis. We calcu-
lated a weighted treatment effect across trials using
fixed-effect model. The results were expressed as relative
risks (RRs) with 95% confidence intervals (CIs) for
dichotomous outcomes. We considered using random-
effects model only in case of heterogeneity (P-value of
c
2 test less than 0.10 and I
2 greater than 50%). Potential
s o u r c e so fh e t e r o g e n e i t yw e r ei d e n t i f i e db ys u b g r o u p
analysis on the basis of G-CSF and GM-CSF or/and by
sensitivity analyses performed by omitting one study in
each turn and investigating the influence of a single
study on the overall meta-analysis estimate. Publication
bias was assessed using funnel plots. A P-value of less
than 0.05 was considered statistically significant. All sta-
tistical analyses were performed using Review Manager,
version 5.0 (RevMan, The Cochrane Collaboration,
Oxford, UK).
Results
Study identification
The comprehensive search yielded a total of 665 rele-
vant publications, and the abstracts were obtained for all
of these (Figure 1). Finally, there were 12 RCTs that met
the inclusion criteria [37-48]. The Cohen К statistic for
agreement on study inclusion was 0.92.
Among the selected trials, three trials were conducted
in North America [40,44,45], two in Europe [43,48], two
in Asia [39,46] and two in Australia [41,47]. Five trials
were multicenter studies [37,38,40,42,48]. Seven trials of
the included 12 trials presented the information of trial
sample calculation of various clinical outcome indices
based on statistical principle (14-day mortality: 1 trial
[43]; 28-day mortality: 2 trials [42,46]; in-hospital mor-
tality: 1 trial [47]; reverse rate from infection: 2 trials
[37,38]; others: 1 trial [48]). Trial samples ranged widely
(18 to 756 patients) with six trials enrolling fewer than
50 patients [39-41,43,44,48]. Of the 2,380 participants
included, 1,188 were randomized to receive G-CSF or
GM-CSF (1,113 received G-CSF and 75 received GM-
CSF) and 1,192 were randomized to receive placebos.
Mean age of patients ranged from 43.2 to 64.5 years.
Among the included 12 trials, 8 trials were designed to
compare G-CSF with placebo and 4 trials compared
GM-CSF with placebo. G-CSF administration included
two regimens (Lenograstim, 263 μg/day; Filgrastim, 300
μg/day) and three of four trials investigating GM-CSF
versus placebo administered GM-CSF with the regimen
of 3 μg/kg/day, the remaining trial 4 μg/kg/day [48].
Patients’ baseline characteristics in comparative groups
were well balanced, such as the Acute Physiology and
Chronic Health Evaluation (APACHE) II score. Only
one trial investigating GM-CSF versus placebo had dis-
crepant baseline characteristics, in which the mean ages
were 62 and 46.5 years old, respectively [41]. Details of
the included studies are summarized in Table 1.
Randomized allocation sequence was adequately gen-
erated in six trials [41-43,46-48], for the other six trials
it was judged to be unclear based on the available docu-
ments [37-40,44,45]. Allocation sequences concealment
was adequately reported in six trials [41,43,44,46-48]
and was judged to be unclear in the other six trials
[37-40,42,45]. It was clearly stated that blinded fashion
was conducted in all but one trial [44] and the outcome
measurements were not likely to be influenced by lack
of blinding. The numbers and reasons for withdrawal/
dropout were detailed reported in all but one trial [42].
None had stopped early due to data-dependent process
or other problems, so free of other sources of bias were
defined across trials. Therefore, five trials [41,43,46-48]
were determined as low risk of bias (plausible bias unli-
kely to seriously alter the results), and six trials
[37-40,42,45] were at unclear risk of bias (plausible bias
that rises up to some doubt about the results), while
one trial [44] was at high risk of bias (plausible bias that
seriously weakens confidence in the results). An over-
view of the quality appraisal was shown in Table 2. For
the meta-analysis of G-CSF or GM-CSF therapy on 28-
day mortality, there was evidence of significant funnel
plot asymmetry (Figure 2).
All-cause mortality at 14 days
In regard to 14-day mortality, only four trials [40,43-45]
consisting of a total of 138 patients evaluated the short-
term outcome. The average sample size for one trial was
34 patients (sample sizes ranged from 18 to 58).
Although one [43] of the four trials had calculated sam-
ple size according to 14-day mortality in the protocol,
fewer patients were enrolled due to lower mortality and
recruitment frequency than anticipated eventually.
Hence, the meta-analysis of these four trials might be
inappropriate to reveal the mortality benefit due to the
limited numbers of patients. Moreover, none of the four
trials reported a significant benefit in 14-day mortality
following GCSF or GM-CSF administration. A total of 9
death events occurred among 71 patients (12.7%) in the
treatment group compared with 13 events among 67
patients (19.4%) in the placebo group.
All-cause mortality at 28 days
Data for 28-day mortality were extracted from nine
trials (n = 2,133) [37,38,40-44,46,48]. There were 177/
1,067 (16.6%) deaths in the treatment group compared
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these trials, there was no significant difference in 28-day
mortality between the treatment group and placebo
group (RR = 0.93, 95% CI: 0.79 to 1.11, P =0 . 4 4 ;P for
heterogeneity = 0.31, I
2 = 15%; Figure 3). Subgroup ana-
lysis of six trials (n = 2,044) [37,38,40,42,43,46] showed
that G-CSF therapy was not associated with a significant
reduction in 28-day mortality (RR = 0.95, 95% CI: 0.80
to 1.14, P = 0.60; P for heterogeneity = 0.13, I
2 =4 1 % ) .
Meanwhile, subgroup analysis of the other three trials of
GM-CSF (n = 89) [41,44,48] did not show significant
difference (RR = 0.66, 95% CI: 0.31 to 1.40, P = 0.28; P
for heterogeneity = 0.91, I
2 = 0%).
In-hospital mortality
In-hospital mortality for patients who were treated with
G-CSF or GM-CSF was 54/501 (10.8%), and that for
patients treated with placebo was 54/495 (10.9%),
according to five trials [37,39,41,44,47] with available
data. Compared with placebo, G-CSF or GM-CSF ther-
apy was not associated with a significant reduction in
in-hospital mortality, and no heterogeneity was detected
across trials (RR = 0.97, 95% CI: 0.69 to 1.36, P = 0.86;
P for heterogeneity = 0.80, I
2 = 0%; Figure 4). Subgroup
analysis of three trials (n = 945) [37,39,47] showed that
G-CSF therapy was not associated with a significant
reduction in in-hospital mortality (RR = 0.99, 95% CI:
Figure 1 Flow-chart of study selection.
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2 =
0%). Meanwhile, subgroup analysis of the other two
trials of GM-CSF (n = 51) [41,44] did not show signifi-
cant difference between the GM-CSF group and placebo
group (RR = 0.90, 95% CI: 0.47 to 1.75, P =0 . 7 6 ;P for
heterogeneity = 0.38, I
2 = 0%).
Reversal rate from infection
Data for reversal rate from infection were available from
four studies [37-39,44]. The incidence of reversal from
infection in treatment group was 190/647 (29.4%) and
placebo was 141/647 (21.8%). Compared with placebo,
G-CSF or GM-CSF therapy was associated with a signif-
icant increase in reversal rate from infection, and no
heterogeneity was detected across trials (RR = 1.34, 95%
CI: 1.11 to 1.62, P = 0.002; P for heterogeneity = 0.47, I
2
= 0%; Figure 5). Subgroup analysis of three trials (n =
1,261) [37-39] showed that G-CSF therapy was asso-
ciated with a significant increase in reversal rate from
infection (RR = 1.30, 95% CI: 1.07 to 1.58, P = 0.007;
P for heterogeneity = 0.84, I
2 = 0%). The other one trial
of GM-CSF (n = 33) [44] also show significant differ-
ence (RR = 2.33, 95% CI: 1.09 to 4.97, P = 0.03).
Adverse events
Overall, there were no significant differences in adverse
events between treatment group and placebo group
according to the data from seven trials (RR = 0.93, 95%
CI: 0.70 to 1.23, P = 0.62) [37,38,40,42,43,45,47], with het-
erogeneity among the trials (P for heterogeneity = 0.03,
Table 1 Characteristics of included randomised controlled trials
Patients
Study Design Treatment
groups
APACHE II
score
N Age (Y) Male/
female
Intervention
Nelson 1998 [37] 2 parallel groups,
71 centers
G-CSF 16.1 380 63.4 ± 16.4 235/145 Filgrastim: 300 μg/d,
subcutaneous, 10 days
Placebo 17.0 376 64.5 ± 15.2 254/122
Nelson 2000 [38] 2 parallel groups,
105 centers
G-CSF 14.5 237 61.1 ± 17.3 138/99 Filgrastim: 300 μg/d,
subcutaneous, 10 days
Placebo 15.5 243 62.3 ± 17.4 153/90
Tanaka 2001 [39] 2 parallel groups, 1 center G-CSF 18.0 12 49.8 ± 6.4 11/1 Lenograstim: 2 μg/kg/d,
intravenous, 5 days
Placebo 15.9 13 54.8 ± 5.7 9/4
Wund 2001 [40] 2 parallel groups, 3 centers G-CSF 25.0 12 49.5 8/4 Filgrastim: 300 μg/d,
intravenous, 10 days
Placebo 31.5 6 56.5 4/2
Presneill
2002 [41]
2 parallel groups, 1 center GM-CSF 12 10 62 7/3 Molgramostim:3 μg/kg/d,
intravenous, 5 days
Placebo 10 8 46.5 6/2
Root 2003 [42] 2 parallel groups, 96
centers
G-CSF 24.3 ± 7.5 348 58.9 ± 17.1 240/108 Filgrastim: 300 μg/d,
intravenous, 5 days
Placebo 24.2 ± 6.9 353 60.0 ± 16.4 247/106
Hartma 2005 [43] 2 parallel groups, 1 center G-CSF 13 13 66 2/11 Filgrastim: 300 μg/d,
subcutaneous, 7 days
Placebo 12.5 16 63 5/11
Rosen 2005 [44] 2 parallel groups, 1 center GM-CSF _ 18 56 8/10 Sargramostim: 3 μg/kg/d,
intravenous, 3 days
Placebo _ 15 52 9/6
Orozco 2006 [45] 2 parallel groups, 1 center GM-CSF 7.3 ± 6.3 28 43.2 ± 15.9 13/15 Molgramostim: 3 μg/kg/d,
subcutaneous, 4 days
Placebo 7.7 ± 6.4 30 49.2 ± 16.5 16/14
Cheng 2007 [46] 2 parallel groups, 1 center G-CSF 22 30 61 _ Lenograstim: 263 μg/d,
intravenous, 3 days
Placebo 22 30 57 _
Stephens
2008 [47]
2 parallel groups, 1 center G-CSF 22.5 ± 7.6 81 51.0 ± 15.1 45/36 Lenograstim: 263 μg/d,
intravenous, 10 days
Placebo 23.4 ± 8.2 83 48.9 ± 16.1 45/38
Meisel 2009 [48] 2 parallel groups, 3 centers GM-CSF 21.3 ± 6.1 19 64.0 ± 13.6 16/3 GM-CSF: 4 μg/kg/d,
subcutaneous, 8 days
Placebo 22.5 ± 6.6 19 63.3 ± 14.2 15/4
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2 = 58%). On the basis of the results of the sensitivity ana-
lysis, one study was excluded [37]. Exclusion of the study
did not significantly change the results of adverse events
(RR = 1.05, 95% CI: 0.84 to 1.32, P = 0.44; P for heteroge-
neity = 0.17, I
2 =3 6 % ;F i g u r e6 ) .
Discussion
During the past few decades, there were a variety of
trials investigating the effect of G-CSF or GM-CSF ther-
apy in patients with sepsis. However, consistent results
have not been reported and no individual study has defi-
nitively established whether G-CSF or GM-CSF bring
clinically important benefitst os e p t i cp a t i e n t s .I nt h e
present meta-analysis, we found no significant differ-
ences in all-cause mortality at 14 days or 28 days, in-
hospital mortality, or adverse events between the G-CSF
or GM-CSF group and placebo group in adult patients
with sepsis. However, our result indicated that G-CSF
or GM-CSF therapy was associated with a significant
increase in reversal rate from infection.
With respect to mortality, a previous meta-analysis
suggested that addition of G-CSF or GM-CSF to anti-
biotic therapy in preterm infants with suspected sys-
temic infection did not significantly reduce all cause
mortality at 14 days or in-hospital mortality [31].
Recently, another meta-analysis showed that administra-
tion of G-CSF was not associated with improved 28-day
mortality in adults with pneumonia [49]. Our meta-ana-
lysis, which included 12 relevant RCTs comparing G-
CSF or GM-CSF with placebo, demonstrated that G-
CSF or GM-CSF therapy did not significantly reduce all
cause mortality at 14 days or 28 days or in-hospital
mortality in patients with sepsis. However, a previous
trial showed that receipt of G-CSF was associated with a
longer duration of survival (P = 0.05) in severe septic
patients due to melioidosis [46]. Meanwhile, another
study demonstrated that GM-CSF significantly reduced
the length of in-hospital stay in patients with nontrau-
matic abdominal sepsis (P <0.001) [45]. However, it
s h o u l db en o t e dt h a te x c e p to n et r i a lb yM e i s e let al.
[48], none of the included trials in this meta-analysis
were designed with patient stratification, whereas drug
efficacy should be assessed only in patients with before-
hand established impairment in monocytic functions
[14]. Immunological biomarkers were thus needed that
allow guidance of immunotherapy, risk stratification,
and determination of which individuals might benefit
from a given intervention [7]. As opposed to circulating
cytokines, the major advantage of measuring mHLA-DR
was that its level of expression was resultant of the sum
of the effects of multiple mediators during septic shock
[ 1 4 ] .A tp r e s e n t ,t h e r ew a sageneral consensus that a
diminished mHLA-DR expression may be a reliable
marker for immunosuppression in critically ill patients
[50,51]. Recently, Meisel and colleagues [48] explored
the GM-CSF therapy versus placebo in sepsis, the first
mHLA-DR-guided immunostimulatory treatment, indi-
cating that administration of GM-CSF to patients in the
immunosuppressive phase of sepsis reversed the charac-
teristic monocyte deactivation as demonstrated by an
increase in mHLA-DR levels and Toll-like receptor-4-
and Toll-like receptor-2-induced cytokine production,
and reduced time of mechanical ventilation as well as
length of hospital and intensive care unit stay. However,
their study was not designed to explore the survival ben-
efits of GM-CSF in sepsis so that it was insufficiently
powered to evaluate mortality. Therefore, more RCTs
with large number of patients to evaluate clinical para-
meters and mortality as primary endpoints were needed
to investigate the effects of mHLA-DR-guided G-CSF or
GM-CSF therapy in patients with sepsis-associated
immunosuppression.
Table 2 Assessing risk of bias
First author year Sequence
generation
Allocation
concealment
Blinding Incomplete
outcome
data addressed
Selective outcome
reporting
Free of other
bias
Summary risk
of bias
Nelson 1998 [37] Unclear Unclear Yes Yes Yes Yes Unclear
Nelson 2000 [38] Unclear Unclear Yes Yes Yes Yes Unclear
Tanaka 2001 [39] Unclear Unclear Unclear Yes Yes Yes Unclear
Wund 2001 [40] Unclear Unclear Yes Yes Yes Yes Unclear
Presneill 2002 [41] Yes Yes Yes Yes Yes Yes Low
Root 2003 [42] Yes Unclear Yes Unclear Yes Yes Unclear
Hartma 2005 [43] Yes Yes Yes Yes Yes Yes Low
Rosen 2005 [44] Unclear Yes No Yes Yes Yes High
Orozco 2006 [45] Unclear Unclear Yes Yes Yes Yes Unclear
Cheng 2007 [46] Yes Yes Yes Yes Yes Yes Low
Stephens 2008 [47] Yes Yes Yes Yes Yes Yes Low
Meisel 2009 [48] Yes Yes Yes Yes Yes Yes Low
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functions that were critical in infectious diseases, such as
neutrophil, monocyte, and macrophage activation and
increased circulating white blood cells [52-54]. In a series
of nine consecutive septic patients with immunosuppres-
sion, the administration of GM-CSF induced a sustained
mHLA-DR recovery, which was accompanied by a
restoration in ex vivo tumor necrosis factor (TNF)-a pro-
duction after LPS challenge [55]. Moreover, in surgical
patients, Schneider et al. observed that G-CSF-induced
restoration of mHLA-DR was not only accompanied by
an increased lymphocyte proliferation and Th1 cytokine
production (interleukine (IL)-2 and interferon (IFN)-g)i n
response to PHA but also by a better capacity to release
inflammatory cytokines in a whole blood model after LPS
challenge [56]. Theoretically, G-CSF and GM-CSF might
benefit patients with sepsis-associated immunosuppres-
sion and result in markedly increase in reversal rate from
infection. Recently, Orozco et al. demonstrated that addi-
tion of GM-CSF to the standard treatment of patients
with nontraumatic abdominal sepsis reduced the rate of
infectious complications, shorten the duration of
antibiotic therapy and the length of hospital stay [45].
Rosen and colleagues [[44] observed a higher leukocyte
count, increased mHLA-DR, and better cure/improve-
ment of infection in GM-CSF group. Results from our
present meta-analysis were in line with the above results
and revealed a significant increase in reversal rate from
infection with G-CSF or GM-CSF therapy verse placebo
(RR = 1.34, 95% CI: 1.11 to 1.62, P = 0.002). However, it
did not bring a significant benefit in 28-day mortality (RR
= 0.93, 95% CI: 0.79 to 1.11, P = 0.44). Due to the com-
plexity of sepsis and associated complications, the severity
of sepsis varied largely. Therefore, G-CSF or GM-CSF
therapy might not be able to bring a significant mortality
benefit if administrated regardless of the specific situation
in individual patient, especially the immunological state
of enrolled patients.
Administration of G-CSF or GM-CSF theoretically may
increase the prevalence of adverse events which include
immunologically mediated organ dysfunction, such as
acute respiratory distress syndrome (ARDS), to which
patients with severe sepsis are particularly prone [49].
However, Tanaka et al demonstrated that G-CSF caused
Figure 2 Funnel plot of the meta-analysis. Funnel plot for the outcome of 28-day mortality associated with G-CSF or GM-CSF therapy
compared with placebo in patients with sepsis.
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without inducing lung injury in septic patients [39].
Another two studies showed that administration of G-
CSF appeared to be safe in patients with pneumonia and
severe sepsis [40,42]. Recently, Presneill et al. demon-
strated that low-dose GM-CSF was associated with
improved gas exchange without pulmonary neutrophil
infiltration and was not associated with worsened acute
respiratory distress syndrome or the multiple organ dys-
function syndromes in patients with sepsis-associated
respiratory dysfunction [41]. Consistent with these stu-
dies, our meta-analysis suggested that G-CSF or GM-CSF
therapy did not significantly increase the rate of adverse
events (RR = 0.93, 95% CI: 0.70 to 1.23, P =0 . 6 2 ;Pf o r
heterogeneity = 0.03, I
2 = 58%). Definitions of adverse
events in included studies were heterogeneous and some-
times absent, which might bring about heterogeneity.
Sensitivity analysis did not significantly change the results
of adverse events (RR = 1.05, 95% CI: 0.84 to 1.32, P =
0.44; P for heterogeneity = 0.17, I
2 =3 6 % ) .
There are several limitations that need to be consid-
ered in the present study. First, the geographic regions
covered in this meta-analysis included North America
(United States, Mexico and Canada), Europe (Belgium,
Germany and Spain), Asia (Japan and Thailand) and
Oceania (Australia). Therefore, our results limited gen-
eralizability to other regions (for example, Africa and
Latin America). Second, considerable heterogeneity
existed in the type and dosage of G-CSF and GM-CSF.
Different baseline characteristics such as age and
APACHE II score might have affected the outcome of
patients’ response to medical management and might
have produced possible clinical heterogeneity. Finally,
the sample sizes were highly variable across trials and
the trial enrolling the maximum number of patients [37]
contained 42 times as many subjects as the two trials
enrolling the minimum number of patients [40,41].
Conclusions
While this meta-analysis demonstrated that G-CSF or
GM-CSF therapy significantly increased the reversal rate
from infection, it was not associated with a significant
reduction in all cause mortality at 14 days or 28 days,
in-hospital mortality or adverse events in patients with
sepsis. Therefore, our present meta-analysis did not sug-
gest routine use of G-CSF or GM-CSF in patients with
Figure 3 28-day mortality of G-CSF or GM-CSF therapy versus placebo. Fixed-effect model of risk ratio (95% confidence interval) of 28-day
mortality associated with G-CSF or GM-CSF therapy compared with placebo.
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Page 8 of 12Figure 4 In-hospital mortality of G-CSF or GM-CSF therapy versus placebo. Fixed-effect model of risk ratio (95% confidence interval) of in-
hospital mortality associated with G-CSF or GM-CSF therapy compared with placebo.
Figure 5 Reversal rate from infection of G-CSF or GM-CSF therapy versus placebo. Fixed-effect model of risk ratio (95% confidence
interval) of reversal rate from infection associated with G-CSF or GM-CSF therapy compared with placebo.
Bo et al. Critical Care 2011, 15:R58
http://ccforum.com/content/15/1/R58
Page 9 of 12sepsis. Large prospective multicenter clinical trials inves-
tigating mHLA-DR-guided G-CSF or GM-CSF therapy
in patients with sepsis-associated immunosuppression
are warranted.
Key messages
￿ The literature shows that G-CSF or GM-CSF result
in no differential effectiveness in treating sepsis, in
t e r m so fa l l - c a u s em o r t a l i t ya t1 4d a y so r2 8d a y s ,
in-hospital mortality or adverse events. However, G-
CSF or GM-CSF therapy significantly increased the
reversal rate from infection in patients with sepsis.
￿ There was a lack of consensus in the literature in
regard to the effect of G-CSF or GM-CSF versus
placebo in treating sepsis in adults.
￿ Larger prospective randomized controlled trials
investigating monocytic HLA-DR (mHLA-DR)-
g u i d e dG - C S Fo rG M - C S Ft h e r a p yi ns e p s i sa r e
warranted.
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